Vinorelbine (VRB) plus gemcitabine (GEM) as first-line treatment for elderly patients (p) with advanced non-small cell lung cancer (NSCLC): Molecular correlates

18040 Background: The clinical benefit of non-cisplatin doublets vs a single agent in elderly or unfit p is still controversial. The present study focuses on clinical outcome with VRB/GEM in elderl...